Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Ar­riVent Bio­phar­ma, a Penn­syl­va­nia drug­mak­er de­vel­op­ing a Chi­na-ap­proved can­cer treat­ment for the US and oth­er ge­o­gra­phies, plans to raise net pro­ceeds of about $135 mil­lion in its Nas­daq list­ing.

It would be the sec­ond biotech IPO of the year af­ter CG On­col­o­gy last week out­lined its pitch for a $181 mil­lion Wall Street de­but.

Ar­riVent plans on sell­ing 8.33 mil­lion shares in its IPO and ex­pects to price at $17 to $19 per share $AVBP, per a Mon­day morn­ing SEC fil­ing. Biotechs tend to go pub­lic with­in a week of pen­cil­ing in their price range.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER